Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14679172 | 0.87 | LMNA (0.57) | LMNATSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL22280529 | 0.74 | HDAC2 (0.54) | LMNATSHRALDH1A1RAB9ANPC1 | |
| SCHEMBL26185952 | 0.74 | CTSL (0.43) | KMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7276838 | 0.73 | ALDH1A1 (0.67) | ALDH1A1 | |
| SCHEMBL14153549 | 0.72 | HDAC1 (0.49) | LMNATSHRKMT2AALDH1A1NPC1 | |
| SCHEMBL28668539 | 0.71 | RAB9A (0.52) | TSHRKMT2AALDH1A1RAB9ANPC1 | |
| SCHEMBL14736018 | 0.70 | TSHR (0.54) | LMNATSHRKMT2AALDH1A1HTT | |
| SCHEMBL1935158 | 0.70 | SLC26A6 (0.36) | TSHRKMT2AALDH1A1 | |
| SCHEMBL29496372 | 0.70 | SPHK1 (0.53) | LMNATSHRALDH1A1RAB9ANPC1 | |
| SCHEMBL315371 | 0.69 | ACACB (0.55) | LMNATSHRKMT2AALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367668-B2 | Pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-02-05 | — | — | US | disclosed |
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2150539-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008145243-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179148-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, RET | LMNA 2650/4885TSHR 421/4885KMT2A 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.